In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.
Did you know that your browser is out of date? To get the best experience using our website we recommend that you upgrade to a newer version. Learn more.

Heart patients set to receive treatment tailored to their genetic and health information

Artificial Intelligence (Machine Learning, Deep Learning)
Cardiovascular Disease in Primary Care
Genetics, Epigenetics, ncRNA

Topics: Cardiovascular disease, genetics, artificial intelligence

Sophia Antipolis, 12 February 2024:  An innovative project using artificial intelligence (AI) to personalise therapies for patients with cardiovascular disease has kicked off at a meeting in Utrecht, the Netherlands.

The NextGen project has received €7.6 million from the EU’s Horizon Europe programme, a €3.1 million grant by the Swiss State Secretariat for Education, Research and Innovation (SERI), as well as the UK Research and Innovation (UKRI) under the UK government’s Horizon Europe funding guarantee. NextGen will be delivered by a 21-member consortium, including the European Society of Cardiology (ESC).1

Cardiovascular diseases (CVDs) are the leading cause of death globally, accounting for nearly 18 million fatalities every year.2 In the EU, CVDs are responsible for approximately one in three deaths.3 CVD comes with a high price, and is estimated to cost the EU €282 billion annually, equivalent to 2% of Europe’s GDP.4 CVD also takes its toll on individuals, often leading to disability, absence from work, premature retirement, and absenteeism.

Personalised medicine, whereby prevention and treatment of disease is tailored to an individual’s unique genetic make-up and health information, holds promise for shifting the dial on the burden of CVD. Now is the time to harness the potential of individualised treatment. Genetic information is more readily available than ever before as the cost of laboratory analysis continues to fall, and cutting edge AI techniques make it possible to combine vast amounts of data in record time.

NextGen will capitalise on these trends by bringing together clinical research organisations, universities, small and medium-sized enterprises (SMEs), and professional associations to integrate multiple sources of data on individual people. This work is complex due to data privacy and governance requirements, the presence of multiple standards across Europe, varying formats of data, and the sheer volume of information.

The first step will be to map out the initiatives already underway to ensure that the project is truly ground-breaking and meets an unmet need. Consortium members will then develop novel tools to merge different types of data in a secure way that upholds individual privacy and allows the information to be used in research. The effectiveness of the methods for removing current barriers to data integration in CVD will be demonstrated in real-world pilot studies.

The work will complement the 1+ Million Genomes initiative, which aims to enable secure access to genomics and clinical data across Europe, and the European Health Data Space, a European Commission governance framework for the safe and secure exchange, use and reuse of health data.

Consortium member Professor Panos Deloukas of Queen Mary University of London, UK, said: “This is a tremendous opportunity and a challenge we have in building the right toolbox that will allow [us] to unite CVD patient data across Europe and implement precision medicine to improve  cardiovascular healthcare.”

Project coordinator Professor Pim van der Harst of University Medical Center Utrecht, the Netherlands, said: “No two people are exactly the same, and so it makes sense that each person needs a slightly different strategy to optimise their health. Personalised medicine is therefore the way forward for preventing heart disease, speeding up diagnosis, and monitoring and treating people with CVD. To develop individualised therapies, we need to compile as much information as possible about individuals, and that’s where NextGen comes in. The unique picture we generate will then form the basis for improving cardiovascular health and wellbeing.”


Notes to editor

Authors: ESC Press Office
Tel: +33 (0)489 872 075

Follow us on X: @ESCardioNews 

Funding: NextGen has received funding from the European Union's Horizon Europe programme under grant agreement ID 101136962, a €3.1 million grant by the Swiss State Secretariat for Education, Research and Innovation (SERI) as well as the UK Research and Innovation (UKRI) under the UK government’s Horizon Europe funding guarantee [grant number 101136962 and 10098097]. 

References and notes

1Consortium coordinator:

  • University Medical Center Utrecht, the Netherlands

Consortium members:

  • DataPower, Italy
  • DPO Associates Sàrl, Switzerland
  • Drug Information Association, Switzerland
  • Earlham Institute, UK
  • EURECOM, France
  • European Society of Cardiology, France
  • Goethe University, Frankfurt, Germany
  • HIRO-MicroCataCenters B.V., the Netherlands
  • HL7 International Foundation, Belgium
  • Human Colossus Foundation, Switzerland
  • HUS, Finland
  • Karolinska Institute, Sweden
  • LiKe Healthcare Research GmbH, Germany
  • MyData Global, Finland
  • NEBS, Belgium
  • Queen Mary University of London, UK
  • Scuola Universitaria Professionale della Svizzera Italiana, Switzerland
  • Technical University of Münich, Germany
  • University of Virginia, US
  • WellSpan Health, US

2World Health Organization:


4Luengo-Fernandez R, Walli-Attaei M, Gray A, et al. Economic burden of cardiovascular diseases in the European Union: a population-based cost study. Eur Heart J. 2023;44(45):4752-4767. doi: 10.1093/eurheartj/ehad583.

About the European Society of Cardiology

The European Society of Cardiology brings together health care professionals from more than 150 countries, working to advance cardiovascular medicine and help people lead longer, healthier lives.